Role of surgery in the treatment of patients with high-risk neuroblastoma who have a poor response to induction chemotherapy

Abstract

BackgroundIn instances of high-risk neuroblastoma that do not show a clinical response to induction therapy, whether it is worth performing surgical resection or not and whether gross total resection (GTR) is more important than subtotal resection (STR) remain controversial. MethodsWe retrospectively analyzed the data of patients with stage 4 neuroblastoma aged 18months or older at diagnosis. Primary tumor volumes were measured both at diagnosis and at the first tumor response evaluation (after 6cycles of induction chemotherapy). If the tumor volume at the first response evaluation was>50% of the initial tumor volume, the patient was categorized as a poor responder. Otherwise, the patient was categorized as a good responder. Only poor responders were included. Patients were evaluated for event-free survival (EFS), overall survival (OS), and complications of surgery based on extent of surgical intervention. ResultsSixty-five patients were included in this study. The 41 patients who underwent surgical intervention had a higher 3-year OS than the 24 patients who had a biopsy only (55.4%±8.1% vs. 31.3%±10.2%, P=0.02). However, there was limited improvement in 3-year EFS following surgical intervention. Three-year EFS rates of BX group (biopsy only) and OP group (surgical resection) were 24.2%±9.3% and 37.7%±7.9%, respectively (P=0.063). The extent of resection had no impact on 3-year OS (P=0.631) and 3-year EFS (P=0.796). Patients in the GTR group trended to have more severe surgical complications than patients in the STR group (P=0.105). ConclusionsFor high-risk neuroblastomas that do not show a clinical response to induction therapy, surgical resection is important in predicting outcome, but the extent of resection is not.